Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 678-685

  Syrbe, Uta ^a   Callhoff, Johanna ^b   Conrad, Kristina ^a   Poddubnyy, Denis ^a   Haibel, Hildrun ^a   Junker, Susann ^c   Frommer, Klaus W ^c   Müller Ladner, Ulf ^c   Neumann, Elena ^c   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; METHOTREXATE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; RESISTIN; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINE RADIOGRAPHY; STEROID THERAPY; AGED; BLOOD; MIDDLE AGED; PROGNOSIS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SPINE;

ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; RESISTIN; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING;

EID: 84923555050     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38968     Document Type: Article

References (47)

1. Sieper J,. Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther 2009; 11: 208.
2. Sieper J,. Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumatol 2009; 21: 335-9.
3. Fantuzzi G,. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9.
4. Schaffler A, Scholmerich J,. Innate immunity and adipose tissue biology. Trends Immunol 2010; 31: 228-35.
5. Havel PJ,. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51-9.
6. Ouchi N, Parker JL, Lugus JJ, Walsh K,. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
7. Shibata R, Ouchi N, Murohara T,. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608-14.
8. Nuttall ME, Shah F, Singh V, Thomas-Porch C, Frazier T, Gimble JM,. Adipocytes and the regulation of bone remodeling: a balancing act. Calcif Tissue Int 2014; 94: 78-87.
9. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 2703-13.
10. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006; 21: 1648-56.
11. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol 2006; 176: 4468-78.
12. Kontny E, Plebanczyk M, Lisowska B, Olszewska M, Maldyk P, Maslinski W,. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis 2012; 71: 262-7.
13. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 2829-39.
14. Neumann E, Frommer KW, Vasile M, Muller-Ladner U,. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? [review]. Arthritis Rheum 2011; 63: 1159-69.
15. 2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 2008; 58: 1399-409.
16. Choi HM, Lee YA, Lee SH, Hong SJ, Hahm DH, Choi SY, et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009; 11: R161.
17. Giles JT, van der Heijde DM, Bathon JM,. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1562-8.
18. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1906-14.
19. Kocabas H, Kocabas V, Buyukbas S, Melikoglu MA, Sezer I, Butun B,. The serum levels of resistin in ankylosing spondylitis patients: a pilot study. Rheumatol Int 2010; 32: 699-702.
20. Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huede G, Saas P, et al. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007; 56: 1383-9.
21. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60: 717-27.
22. Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
23. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011; 70: 249-51.
24. Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL,. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127-9.
25. Youden WJ,. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
26. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64: 1388-98.
27. Swarbrick MM, Havel PJ,. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102.
28. Gheita TA, El-Gazzar II, El Shazly RI, El-Din AM, Abdel-Rasheed E, Bassyouni RH,. Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity. J Clin Immunol 2013; 33: 297-301.
29. De Boer TN, van Spil WE, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP, et al. Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 2012; 20: 846-53.
30. Yoshino T, Kusunoki N, Tanaka N, Kaneko K, Kusunoki Y, Endo H, et al. Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Intern Med 2011; 50: 269-75.
31. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458-63.
32. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007; 19: 1070-4.
33. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, et al. Anti-TNF-a therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
34. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Berja A, Miranda-Filloy JA, de Matias JM, et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-a therapy. Clin Exp Rheumatol 2010; 28: 56-62.
35. Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl LH, Nurmohamed MT, et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 2012; 71: 1510-6.
36. Auguet T, Terra X, Porras JA, Orellana-Gavalda JM, Martinez S, Aguilar C, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem 2013; 46: 202-8.
37. Kim KS, Choi HM, Ji HI, Song R, Yang HI, Lee SK, et al. Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment. Mol Med Rep 2014; 9: 255-60.
38. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 1369-74.
39. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 1846-53.
40. Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2014; 73: 2137-43.
41. Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 2014; 73: 1746-8.
42. Appel H, Maier R, Loddenkemper C, Kayser R, Meier O, Hempfing A, et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol 2010; 37: 823-8.
43. Bleil J, Maier R, Hempfing A, Schlichting U, Appel H, Sieper J, et al. Histomorphological and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. Arthritis Rheumatol 2014; 66: 1745-54.
44. Duan Y, Hao D, Li M, Wu Z, Li D, Yang X, et al. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int 2012; 32: 985-90.
45. Laiguillon MC, Houard X, Bougault C, Gosset M, Nourissat G, Sautet A, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther 2014; 16: R38.
46. Chen WP, Bao JP, Feng J, Hu PF, Shi ZL, Wu LD,. Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. Clin Chem Lab Med 2010; 48: 1141-5.
47. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007; 80: 201-10.